Independent register of U.S. FDA drug recalls · updated Oct 10, 2026
RxRecalls Get alerts
Class II · Moderate risk Ongoing Initiated May 20, 2021 (5 years ago)

Daytrana (methylphenidate transdermal system)

Class II — Moderate risk. May cause temporary or reversible harm; serious harm unlikely.

Why it was recalled

Defective Delivery System: The number of customer complaints for ripping patches and tight release/adhesive transfer have exceeded the action limits.

Cause type: Packaging defect

Failed child-resistant closures, leaks, cracked containers, or a defective delivery device. Packaging failures risk accidental exposure (especially to children) or product contamination. All packaging defect recalls.

What was recalled

Daytrana (methylphenidate transdermal system), Delivers 15 mg over 9 hours (1.6 mg/hr), 30 Patches (NDC 68968-5553-1) per box (NDC 68968-5553-3), Rx only, Manufactured for Noven Therapeutics, LLC., Miami, FL 33186; By Noven Pharmaceuticals, Inc., Miami, FL 33186.

Affected NDCs 68968-5553-01 68968-5553-03

Compare with the code on your package — it is the most precise check available.

Drug: Methylphenidate

Product details

From the FDA NDC directory, for the product code this recall names. Compare with the label on your package.

ProductStrengthForm & routeLabelerType
Daytrana
methylphenidate
NDC 68968-5553		 15 mg/9h Patch
Transdermal		 Noven Therapeutics, LLC Rx · CII
Recalling firm
Noven Pharmaceuticals Inc
NDC code
68968-5553-1
Origin
FL, United States
Initiated by
Voluntary: Firm initiated
FDA recall number
D-0394-2021 · FDA notice

Check, then ask. Class II means harm is possible but usually temporary or reversible. Find the lot number on your package; if it matches, ask your pharmacist about a replacement. Do not simply stop a prescribed medication on your own - the gap can be riskier than the recall.

Other Methylphenidate recalls

See all
Class II · Moderate risk

Methylphenidate Hydrochloride

Failed dissolution specifications: this product is being recalled due to this batch not meeting dissolution specifications.

Terminated Dissolution failure Trigen Laboratories NDC 13811-708-10 D-0579-2024

Other recalls by Noven Pharmaceuticals Inc

All 2021 recalls
Class II · Moderate risk

Xelstrym (dextroamphetamine)

Defective Delivery System: The product does not meet predetermined specifications for Coldflow (adhesive).

Ongoing Packaging defect Noven Pharmaceuticals Inc NDC 68968-0215-3 D-0055-2025